Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy
Executive Summary
Schering-Plough is ending its supply management program for PEG-Intron (peginterferon alfa-2b) based on enhanced production capacity for the hepatitis C agent
You may also be interested in...
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling
Pharmacia II? Schering’s Hassan Brings In Former Colleagues; Zahn Leaves
Schering-Plough CEO Fred Hassan is bringing in three more former Pharmacia employees under a restructuring plan intended to globalize operations and eliminate several levels of management